Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:43 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Nicotinic Receptors and Schizophrenia
NCT02538081 · VA Office of Research and Development · PHASE1/PHASE2 · withdrawn · last registry update 2017-05-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Withdrawn” | – | Registry record, VA Office of Research and Development |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HTR2A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-05-22Results posted on the registry: Michelle Weckmann, Haldol (NCT03489551)
- 2018-04-26Phase 3 first posted: Tonix Pharmaceuticals, Inc., TNX-102 SL 5.6 mg (NCT03508700)
- 2018-03-21Also stopped (terminated): UMC Utrecht, Haloperidol + Methylphenidate (NCT00599287)
- 2018-03-14Phase 3 first posted: Bukwang Pharmaceutical, Lurasidone HCL 160 mg + Quetiapine XR 600 mg (NCT03465787)
- 2018-02-28Also stopped (terminated): Hannover Medical School, Phenobarbital + Phenytoin (NCT02374567)
- 2018-01-18Phase 3 first posted: NeuroRx, Inc., NRX-101 + Lurasidone HCl (NCT03402152)
- 2018-01-10Phase 3 first posted: NeuroRx, Inc., NRX-101 + Lurasidone HCl (NCT03395392)
- 2018-01-10Phase 3 first posted: NeuroRx, Inc., NRX-101 + Lurasidone HCl (NCT03396068)
- 2018-01-02Results posted on the registry: Alexza Pharmaceuticals, Inc., Inhaled Placebo + Inhaled Loxapine 5 mg (NCT00369577)
- 2017-12-20Results posted on the registry: University of Pittsburgh, haloperidol (NCT00300391)
- 2017-12-20Also stopped (terminated): University of Pittsburgh, haloperidol (NCT00300391)
- 2017-12-20Results posted on the registry: Sumitomo Pharma America, Inc., Lurasidone + Placebo (NCT02046369)
- 2017-12-13Results posted on the registry: Alexza Pharmaceuticals, Inc., Lorazepam 1 mg IM + Inhaled loxapine 10 mg (NCT01877642)
- 2017-11-13Results posted on the registry: New York State Psychiatric Institute, Lurasidone (Latuda) (NCT02239094)
- 2017-10-30Phase 3 first posted: ACADIA Pharmaceuticals Inc., Placebo + Pimavanserin 34 mg (NCT03325556)
- 2017-10-25Results posted on the registry: ACADIA Pharmaceuticals Inc., Pimavanserin tartrate + Placebo (NCT02035553)
- 2017-10-23Phase 3 first posted: University Hospital, Clermont-Ferrand, Dexmedetomidine (NCT03317067)
- 2017-10-18Results posted on the registry: Alexza Pharmaceuticals, Inc., ADASUVE 10 mg 2 doses 2 hours apart + Inhaled Placebo (NCT01854710)
- 2017-10-13Results posted on the registry: Cycle Pharmaceuticals Ltd., Chlorpromazine Hydrochloride (NCT02943213)
- 2017-09-25Also stopped (withdrawn): George Washington University, ziprasidone + Standard therapy (NCT00786318)
- 2017-08-17Also stopped (terminated): The University of Texas Health Science Center, Houston, Haloperidol + Conventional Therapy (NCT02057549)
- 2017-07-24Also stopped (withdrawn): Hennepin Healthcare Research Institute, Ketamine + Haloperidol (NCT02103881)
- 2017-07-13Results posted on the registry: The University of Texas Health Science Center, Houston, Haloperidol + Conventional Therapy (NCT02057549)
- 2017-07-07Results posted on the registry: Tonix Pharmaceuticals, Inc., TNX-102 SL (NCT02015234)
- 2017-06-29Results posted on the registry: Alexza Pharmaceuticals, Inc., Inhaled loxapine 5 mg + Inhaled loxapine 10 mg (NCT00628589)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision